Showing 3901-3910 of 6411 results for "".
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- White Coats, Scrubs Top Patient Preferences for Doctor's Attirehttps://practicaldermatology.com/news/white-coats-scrubs-top-patient-preferences-for-doctors-attire/2457735/What doctors wear matters…a lot, according to the largest-ever study of patient preferences for doctors’ attire. Just more than half of the 4,062 patients surveyed in the clinics and hospitals of ten major medical centers said that what physicians wear is important to th
- Avon Receives Patents for Rotational Infinite Effects Skincare Technologyhttps://practicaldermatology.com/news/avon-receives-patents-for-rotational-infinite-effects-skincare-technology/2457739/Avon has been issued two new patents for new technology currently included in the ANEW Reversalist Infinite Effects and most recently the ANEW Ultimate Infinite Effects products. The rotational regimen is designed to
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visithttps://practicaldermatology.com/news/news-you-can-use-simple-one-page-tool-improves-patient-satisfaction-with-doctor-visit/2457805/A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what&rsqu
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep